Researchers Engineered Macrophages to Attack Solid Tumors
Scientists modified immune cells to bypass cancer's survival signals in a new preclinical study.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Should medical research prioritize new immunotherapy techniques to better treat difficult solid tumors?
University of Wisconsin researchers developed a method to genetically engineer stem cell-derived macrophages to target and destroy solid tumor cells. This preliminary research, published October 7, 2026, focuses on improving how immune cells identify and eliminate malignant tissue.
Why it matters
Solid tumors often evade the immune system by hijacking natural wound-healing signals, effectively telling macrophages not to attack. By re-engineering these cells, researchers hope to create more precise cancer therapies that can bypass these protective signals.
In a preclinical study using induced pluripotent stem cell-derived macrophages, researchers demonstrated that removing the SIRPalpha gene allows immune cells to bypass tumor-driven 'don't eat me' signals. These modified macrophages required targeted antigen binding to destroy ovarian, melanoma, and neuroblastoma cancer cells.
The players
University of Wisconsin
An academic institution leading research in biotechnology and cellular therapies for cancer treatment.
The details
Macrophages naturally perform phagocytosis to clear infections and debris, but cancer cells exploit this by expressing the CD47 protein. This protein binds to the macrophage's SIRPalpha receptor, effectively sending a signal that instructs the immune cell to ignore the tumor. By using CRISPR technology to delete the SIRPalpha gene, researchers ensured these macrophages could no longer receive that inhibitory signal. The modified cells were further enhanced with a CAR molecule to ensure they specifically target and destroy tumor cells.
Timeline
October 7, 2026: The research findings were published.
Health Landscape
This work fits into the broader evolution of cellular immunotherapy, which has historically focused on T-cells to combat blood cancers. By targeting macrophages, researchers are attempting to bridge the gap in treating solid tumors that often resist conventional immune-based interventions.
While this preclinical work represents a technical milestone in immunology, it is not yet a treatment available for clinical use. It is worth discussing the status of immune-targeted therapies with your oncologist if you have questions about current cancer research developments.
The takeaway
Targeting the signaling pathways that tumors use to hide from immune cells is a promising area of scientific inquiry. Readers can track advances in immunotherapy research by monitoring updates from established clinical research institutions.
What happens next
The research team plans to initiate preclinical studies in mouse models to observe how these engineered macrophages function and persist within a living system.
Further reading
For more on the current state of cancer therapies, visit the Cancer section.
Source note: This article includes information reported by The Badger Herald.
Live Poll
Should medical research prioritize new immunotherapy techniques to better treat difficult solid tumors?
